RTI Surgical recently unveiled a $15 million expansion of its Class III medical device facility in Alachua, Florida, marking a significant milestone in its commitment to advancing tissue engineering. This extensive overhaul includes the addition of a 5,000 square-foot clean room, drastically enhancing their Tutoplast Tissue Sterilization Process (TTSP) facility. The TTSP plays a pivotal role in preserving human tissue for a wide array of implants crucial in various medical fields, such as plastic and reconstructive surgery, sports medicine, orthopedics, as well as neuro and spine surgery. The primary aim of this expansion is to meet the skyrocketing demand for Tutoplast processed implants while simultaneously supporting RTI’s upcoming clinical study on the effectiveness of the Cortiva Allograft Dermis (ADM) in implant-based breast reconstruction.
Advantages of Expansion and Industry Implications
RTI Surgical’s initiative is not just about expanding square footage; it represents a broader strategy to bolster their manufacturing capabilities and reinforce their unwavering commitment to innovation and excellence in tissue engineering. Olivier Visa, RTI Surgical’s President and CEO, underscored this sentiment, emphasizing that the extension enhances their ability to deliver high-quality products. The Cortiva ADM, processed using TTSP, is widely utilized in soft tissue repair, making it an indispensable component in modern medical procedures. This recent facility upgrade aligns seamlessly with RTI’s recent agreement to acquire Collagen Solutions, a key supplier of medical-grade collagen and xenograft tissue. Together, these developments mark a significant leap in RTI’s growth trajectory within the burgeoning field of regenerative medicine, positioning the company at the forefront of technological advancements and industry integration.
